miR-190和ANXA11对直肠癌新辅助放化疗效用评估价值及相关性分析  

Evaluation and Correlation Analysis of the Therapeutic Value of miR-190 and ANXA11 in Neoadjuvant Chemoradiotherapy for Rectal Cancer

作　　者：徐钰 胡锡池[2] 赵于天 XU Yu(The Affiliated Hospital of Jiangnan University,Jiangsu Wuxi 214122,China)

机构地区：[1]江南大学附属医院腹部放疗科,江苏无锡214122 [2]江苏省无锡市第二人民医院检验科,江苏无锡214002

出　　处：《河北医学》2023年第12期1946-1951,共6页Hebei Medicine

基　　金：江苏省卫生健康委医学科研项目(编号:2020215)。

摘　　要：目的:分析微小核苷酸190(miR-190)及膜联蛋白A11(ANXA11)在直肠癌新辅助放化疗(NAC)评估中的作用及相关性。方法:选取2019年6月至2022年8月在我院确诊为直肠癌并接受治疗的148例患者作为研究对象,将其纳入直肠癌组,另选取同时期150例健康人作为对照组。实时荧光定量检测(RT-PCR)检测两组受试者血清miR-190、ANXA11 mRNA表达;对所有直肠癌患者术前均采用相同新辅助放化疗(NAC),按照疗效评估标准分为疗效优良组(n=89)与疗效较差组(n=59),对比两组患者血清miR-190、ANXA11 mRNA表达,分析血清miR-190、ANXA11 mRNA表达与临床疗效的关系;绘制Kaplan-meier观察miR-190、ANXA11 mRNA高低表达对NAC临床疗效影响;ROC分析miR-190、ANXA11单一及联合检测对NAC临床效用评估价值。结果:相比于对照组,直肠癌患者miR-190表达显著降低,而ANXA11 mRNA表达显著升高(0.87±0.18vs1.53±0.30、2.00±0.68vs0.95±0.09,t=-22.719、18.731,P<0.05);相比于疗效较差组,疗效优良组患者miR-190表达显著升高,而ANXA11 mRNA表达显著降低(0.96±0.15vs0.73±0.15、1.81±0.47vs2.28±0.83,t=8.932、-3.958,均P<0.05);Spearman相关系数分析miR-190与NAC疗效呈正相关,而ANXA11 mRNA表达与NAC疗效呈负相关(P<0.05);Kaplan-meier曲线显示,miR-190高表达组患者NAC疗效优良率显著高于miR-190低表达组(χ^(2)=39.120,P<0.001),ANXA11 mRNA低表达组患者NAC疗效优良率显著高于ANXA11 mRNA高表达组(χ^(2)=8.772,P=0.003);ROC显示miR-190、ANXA11联合检测的AUC显著高于单一检测(P<0.05),敏感度为84.75%,特异度为87.64%。结论:miR-190、ANXA11在不同NAC疗效患者中均具有特异性表达特征,并且与NAC疗效之间具有密切联系,通过联合miR-190、ANXA11检测能够有效预测NAC临床效用,为临床评估直肠癌疗效提供新思路。Objective:To analyze the roles and relationship of microRNA 190(miR-190)and membrane-associated protein A11(ANXA11)in the evaluation of neoadjuvant radiotherapy(NAC)for rectal cancer.Methods:A total of 148 patients who were diagnosed with rectal cancer and received treatment in our hospital from June 2019 through August 2022 were selected as the study subjects and included in the rectal cancer group,and 150 healthy people who underwent general physical examination in our hospital during the same period were selected as the control group,and real-time fluorescence quantitative detection(RT-PCR)detected the expression of serum miR-190 and ANXA11 mRNA in the two groups.All rectal cancer patients were treated with the same neoadjuvant radiotherapy and chemotherapy(NAC)before surgery,and were divided into the excellent efficacy group(n=89)and the poor efficacy group(n=59)according to the efficacy assessment criteria,and the serum miR-190 and ANXA11 mRNA expression of the patients in the two groups were compared.Spearman's correlation coefficient was used to analyze the relationship between serum miR-190,ANXA11 mRNA expression and clinical efficacy;Kaplan-meier was plotted to observe the effect of high and low miR-190,ANXA11 mRNA expression on the clinical efficacy of NAC;Subject operating characteristic curves(ROCs)were plotted to analyze the value of miR-190,ANXA11 single and combined assays for clinical utility assessment of NAC.Results:Compared with the control group,miR-190 expression was significantly lower,while ANXA11 mRNA expression was significantly higher in rectal cancer patients(0.87±0.18 vs 1.53±0.30,2.00±0.68 vs 0.95±0.09,t=-22.719,18.731,P<0.05).Compared with the poor-efficacy group,miR-190 expression was significantly higher in patients in the excellent-efficacy group,while ANXA11 mRNA expression was significantly lower(0.96±0.15vs0.73±0.15,1.81±0.47vs2.28±0.83,t=8.932,-3.958,all P<0.05);Spearman correlation coefficient analysis showed that miR-190 was positively correlated with NAC efficacy,wh

关 键 词：直肠癌 miR-190 膜联蛋白A11 

分 类 号：R735.3[医药卫生—肿瘤]